Effectiveness of confidential reports to physicians on their prescribing of antipsychotic medications in nursing homes

Table 4 Prescription rates: pairwise comparisons for changes over 6 months from baseline

Change	Adjusted least square mean difference (% scale)	95% confidence interval	p value
Mean percentage of nursing home days on antipsychotics
Report view vs. no sign up	− 0.94	− 1.54, − 0.35	0.002
No report view vs. no sign up	− 0.47	− 1.09, 0.15	0.137
Report view vs. no report view	− 0.47	− 1.26, 0.31	0.239
Mean percentage of nursing home days on benzodiazepines*
Report view vs. no sign up	− 0.27	− 0.57, 0.02	0.071
No report view vs. no sign up	0.12	− 0.19, 0.44	0.433
Report view vs. no report view	− 0.40	− 0.79, 0.00	0.048
Mean percentage of nursing home days on statins
Report view vs. no sign up	− 0.24	− 0.58, 0.10	0.171
No report view vs. no sign up	0.02	− 0.33, 0.38	0.893
Report view vs. no report view	− 0.26	− 0.72, 0.19	0.254

Multivariable linear mixed effects regression adjusted for the following: nursing home variables (number of beds, urban vs. rural location, private vs. public institution), physician variables (sex, age [cont.], years practicing [cont.], Canadian vs. foreign graduate, number of nursing home residents [cont.], number of nursing home institutions practicing in [cont.], percent of billings in nursing homes), and resident characteristics (sex, age [cont.] time in nursing home [cont.], Charlson comorbidity scale [cont.], diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral vascular disease, deep vein thrombosis, cardiac dysrhythmia, Alzheimer’s, dementia, cancer, obstructive airway disease, depression, arthritis, Parkinson’s disease, activities of daily living scale, pain score, depression rating scale, likelihood of falls scale, aggressive behavior scale, frailty index, emergency room visits in past year [cont.], inpatient hospitalizations in past year [cont.], any psychiatric consult in past year, any geriatric consult in past year, any benzodiazepine use). Analyses restricted to physicians who signed up in time for the initial release of the intervention
*Any benzodiazepine use dropped from adjustment in this model

ISSN: 2662-2211